Traws Pharma, Inc. Q1 2026 Financial Results: Key Highlights for Investors

Introduction

Traws Pharma, Inc. has released its unaudited financial results for the first quarter ended March 31, 2026. The company’s quarterly report, filed with the U.S. Securities and Exchange Commission on Form 10-Q, provides important updates on financial performance, share structure, and other disclosures that are highly relevant to investors and may impact share value.

Key Financial Highlights

• Net Loss: The company reported a net loss of \$7.1 million for Q1 2026, compared to a net income of \$21.5 million in the same period in 2025. This significant swing from profit to loss is a crucial point for shareholders.
• Net Loss Attributable to Common Stockholders: Net loss attributable to common stockholders (basic and diluted) was \$5.7 million for Q1 2026, versus net income of \$15.1 million in Q1 2025.
• Earnings (Loss) Per Share: Net loss per share of common stock, both basic and diluted, was (\$0.53) in Q1 2026, compared to earnings per share of \$2.17 (basic) and \$2.09 (diluted) in Q1 2025. This represents a significant deterioration in per-share profitability.
• Weighted-Average Shares Outstanding: The number of shares outstanding for basic and diluted calculations increased to 10,640,625 in Q1 2026 from 6,965,927 in Q1 2025, indicating share dilution over the year.
• Total Stockholders’ Deficit: At March 31, 2026, the company’s total stockholders’ deficit was (\$5.3 million), compared to (\$629,000) at December 31, 2025, demonstrating a worsening equity position.
• Total Assets: The company’s total assets as of March 31, 2026, stood at \$8.2 million, down from \$10.6 million at the end of 2025.

Share Capital and Structure

• Common Stock: The company has authorized 250,000,000 shares of common stock with a par value of \$0.01 per share. As of March 31, 2026, 15,150,669 shares were outstanding.
• Preferred Stock: The company has authorized 5,000,000 shares of Series C Preferred Stock with a par value of \$0.01 per share, with 6,737 shares issued and outstanding as of March 31, 2026.
• Recent Share Issuances:
  • 1,090,000 shares of common stock were issued in Q1 2026, net of offering costs, raising \$11,000 in new capital.
  • 4,813 shares issued for vested restricted stock units.
• Stock-Based Compensation: The company recognized \$634,000 in share-based compensation expense in Q1 2026.

Other Noteworthy Disclosures

• Exchange Listing: Traws Pharma’s common stock trades on The Nasdaq Stock Market LLC.
• SEC Compliance: The company confirmed it has filed all required reports under Sections 13 or 15(d) of the Securities Exchange Act of 1934 in the preceding 12 months and has submitted all Interactive Data Files required.
• Filer Status: The company is classified as a Non-accelerated filer and a Smaller reporting company. It is not an emerging growth company or shell company.

Potential Price-Sensitive Issues for Shareholders

• Significant Swing to Net Loss: The transition from a strong net income in Q1 2025 to a substantial net loss in Q1 2026 is likely to be viewed negatively by the market and could put downward pressure on the stock price.
• Worsening Equity Position: The increase in stockholders’ deficit suggests financial challenges and may raise concerns about the company’s balance sheet strength and future capital needs.
• Increased Share Count and Dilution: The issuance of additional shares, including new stock from offerings and stock-based compensation, has increased the total shares outstanding, diluting existing shareholders’ ownership and earnings per share.
• Reduced Asset Base: The decline in total assets may indicate ongoing cash burn or asset write-downs, potentially impacting the company’s ability to fund operations.

Conclusion

Traws Pharma, Inc.’s Q1 2026 financial results reveal a challenging quarter characterized by a swing to net loss, balance sheet deterioration, and ongoing dilution of shares outstanding. Shareholders should closely monitor the company’s future disclosures, particularly regarding strategies to restore profitability and strengthen its financial position.